Company Description
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases.
The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes.
It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions.
In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease.
Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease.
The company was founded in 2015 and is headquartered in San Francisco, California.
| Country | Canada |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 54 |
| CEO | Frank L. Karbe |
Contact Details
Address: 548 Market St. #49404 San Francisco, California 94101 United States | |
| Phone | 415-887-2311 |
| Website | bettertx.com |
Stock Details
| Ticker Symbol | BTTX |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001832415 |
| CUSIP Number | 08773T104 |
| ISIN Number | US08773T1043 |
| SIC Code | 8000 |
Key Executives
| Name | Position |
|---|---|
| David P. Perry M.B.A. | Co-Founder and Executive Chairman |
| Frank L. Karbe | Chief Executive Officer, Interim Chief Financial Officer, President and Director |
| Dr. Mark A. Berman M.D. | Chief Medical Officer |
| Kristin Wynholds | Chief Product Officer |
| Andres Camacho | Senior Vice President of Technology and Head of Engineering |
| Angela Willis | Senior Vice President of Market Access |
| Jessica Meng | Chief Commercial Officer |
| Leslie Miller | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 30, 2024 | 15-12G | Securities registration termination |
| May 28, 2024 | EFFECT | Notice of Effectiveness |
| May 28, 2024 | EFFECT | Notice of Effectiveness |
| May 28, 2024 | EFFECT | Notice of Effectiveness |
| May 28, 2024 | EFFECT | Notice of Effectiveness |
| May 28, 2024 | EFFECT | Notice of Effectiveness |
| May 23, 2024 | POS AM | Post-Effective amendments for registration statement |
| May 23, 2024 | POS AM | Post-Effective amendments for registration statement |
| May 23, 2024 | POS AM | Post-Effective amendments for registration statement |
| May 23, 2024 | POS AM | Post-Effective amendments for registration statement |